Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-31
2006-10-31
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S118000, C544S230000, C544S265000, C544S267000, C544S277000, C544S317000, C544S329000, C544S264000, C514S263400, C514S263200, C514S263220, C514S263230, C514S263340
Reexamination Certificate
active
07129239
ABSTRACT:
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.wherein A is an optionally substituted aryl or an optionally substituted heteroaryl; B is an optionally substituted aryl or an optionally substituted heteroaryl; R1is hydrogen, (C1–C4)alkyl, halo-substituted (C1–C4)alkyl, or (C1–C4)alkoxy; and R4is as described herein.
REFERENCES:
patent: 3016378 (1962-01-01), Roch et al.
patent: 3457263 (1969-07-01), Regnier et al.
patent: 3850917 (1974-11-01), Muller et al.
patent: 4459296 (1984-07-01), Ancher et al.
patent: 4728644 (1988-03-01), Yuki et al.
patent: 4925846 (1990-05-01), Deacon et al.
patent: 4944790 (1990-07-01), Moser et al.
patent: 5057517 (1991-10-01), Johnston et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5256398 (1993-10-01), McAfee et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5744491 (1998-04-01), Boigegrain et al.
patent: 5744493 (1998-04-01), Boigegrain et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6100259 (2000-08-01), Xiang et al.
patent: 6166016 (2000-12-01), Okamura et al.
patent: 6284748 (2001-09-01), Dang et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6355631 (2002-03-01), Achard et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 6579868 (2003-06-01), Asano et al.
patent: 6841549 (2005-01-01), Asano et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2001/0053788 (2001-12-01), Lange et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0019421 (2002-02-01), Biberman et al.
patent: 2002/0035102 (2002-03-01), Achard et al.
patent: 2002/0091114 (2002-07-01), Plot-Grosjean et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2002/0128302 (2002-09-01), Maruani et al.
patent: 2002/0188007 (2002-12-01), Barth et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2003/0139386 (2003-07-01), Cote et al.
patent: 2003/0199536 (2003-10-01), Thomas et al.
patent: 2004/0072833 (2004-04-01), Nakai et al.
patent: 2004/0077650 (2004-04-01), Dow
patent: 2005/0043327 (2005-02-01), Coe et al.
patent: 2387138 (2001-04-01), None
patent: 293220 (1994-08-01), None
patent: 1054012 (1998-12-01), None
patent: 1221444 (2000-06-01), None
patent: 1354884 (2003-10-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 00/15609 (2000-05-01), None
patent: WO 01/24798 (2001-04-01), None
patent: WO 01/029007 (2001-04-01), None
patent: WO 01/032629 (2001-05-01), None
patent: WO 01/032663 (2001-05-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 01/85092 (2001-11-01), None
patent: WO02053565 (2002-07-01), None
patent: WO 02/076949 (2002-10-01), None
patent: WO 03/006007 (2003-01-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/018060 (2003-03-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/020314 (2003-03-01), None
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 03/027069 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/075660 (2003-09-01), None
patent: WO 03/077847 (2003-09-01), None
patent: WO 03/078413 (2003-09-01), None
patent: WO 03/082190 (2003-10-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 03/082256 (2003-10-01), None
patent: WO 03/082833 (2003-10-01), None
patent: WO 03/084943 (2003-10-01), None
patent: WO 03/086288 (2003-10-01), None
patent: WO 03/087037 (2003-10-01), None
patent: WO03095455 (2003-11-01), None
Miles et al. Diabetes Care 25 (7): 1123.
Hollander et al. Diabetes Care 21 (8): 1288.
Fujioka, K., et al., Diabetes, Obesity and Metabolism vol. 2 p. 175-187 May 2000.
Tanju, Ken-ichi, et al.,Heterocycles, “Purines. IX.1 Reation of 9-Phenyl-9H-Purine—2-Carbonitriles with Grignard Reagents”, vol. 30, (1), pp. 435-440 (1990).
Halpern, et al.,Obesity Reviews, “Treatment of Obesity: An Update On Anti-Obesity Medications”, vol. 4, pp. 25-42 (2003).
Chorvat, et al.,J. Med. Chem., “Synthesis, Corticortropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo,-Imidazo-, and Pyrrolopyrimidines and —Pyridines”, vol. 42, pp. 833-848 (1999).
Legraverend, et al.,Bioorganic&Medicinal Chemistry Letters, “Synthesis of C2 Alkylnylated Purines, A New Family of Potent Inhibitors of Cyclin-Dependent Kinases”, vol. 8, pp. 793-798 (1998).
Camaionl, et al.,Bioorganic&Medicinal Chemistry, “New Substituted 9-Alkylpurines as Adenosine Receptor Ligands”, vol. 6, pp. 523-533 (1998).
Young, et al.,J. Med. Chem., “Purine Derivatives as Competitive Inhibitors of Human Erythrocyte Membrane Phosphatitdylinositol 4-Kinase”, vol. 33, pp. 2073-2080 (1990).
Montgomery, et al.,Journal of the American Chemical Society, “Synthesis of Potential Anticancer Agents. XXVI. The Alkylation of 6-Choloropurine”, vol. 83, pp. 630-635 (1960).
Koppel, et al.,Journal of Organic Chemistry, “Potential Purine Antagonists. XIII. Synthesis of Some 8-Methylpurines”, vol. 23, pp. 1457-1460 (Oct. 1958).
Ding, et al.,Tetrahedron Letters, “Expanding the Diversity of Purine Libraries”, vol. 42, pp. 8751-8755 (2001).
Tzavara, E.T., et al., “The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medical prefrontal cortex: Implications for Therapeutic Actions,”J Pharmacol, 138, 544-553 (2003).
Racz, I., et al., “A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking,”J Neurosci, 23(6), 2453-2458 (2003).
Croci, T., et al., “Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents,”Brit J Pharmacol, 140, 115-122 (2003).
DaSilva, G.E., et al., “Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats,”Neurosci Let, 349, 49-52 (2003).
Wang, L., et al., “Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice,”PNAS, 100(3), 1393-1398 (2003).
Ruiu, S., et al., “Synthesis and Charaterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor,”J Pharmacol Exp Therap, 306, 363-370 (2003).
Howlett, A.C., et al., “International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors,”Pharmacol Rev, 54, 161-202 (2002).
Gomez, R., et al., “A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding,”J. Neurosci, 22(21), 9612-9617 (2002).
Wiley, J.L., et al., “Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation,”J Pharmacol Exp Therap, 296(3), 1013-1022 (2001).
Lellemand, F., et al., “Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration,”Alcohol Clin Exp Res, 25(9), 1317-1323 (2001).
Pertwee, R.G., “Cannabinoids and the Gastrointestinal Tract,”Gut, 48, 859-867 (2001).
Pertwee, R.G., “Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development,”Ex
Benson Gregg C.
Berch Mark L.
Musser Arlene K.
Pfizer Inc.
LandOfFree
Purine compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purine compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3691213